Intercept Soars on Report of Potential Acquisition Suitors

Intercept Pharmaceuticals Inc., which is developing a liver disease drug that would be its first product, rose 28 percent in its biggest gain in two years after a report that the company is receiving interest from potential acquirers.

The shares rose 28 percent to $120.22 in New York trading, their biggest one-day gain since January 2014. Elliot Fox, an outside spokesman for Intercept, declined to comment on the report from Reuters.